Platelet glycoprotein VI genetic quantitative and qualitative defects
Platelets, 2019 Platelet membrane glycoprotein VI (GPVI) is increasingly recognized as an important receptor for thrombus formation and growth. Numerous arguments have been published indicating that GPVI plays a major role in thrombosis without being essential for ...
Martine Jandrot-Perrus +2 more
doaj +4 more sources
Long-term platelet priming after glycoprotein VI stimulation in comparison to Protease-Activating Receptor (PAR) stimulation. [PDF]
PLoS ONE, 2021 Platelets can respond to multiple antagonists and agonists, implying that their activation state is a consequence of past exposure to these substances.
Jinmi Zou +3 more
doaj +2 more sources
Glycoprotein VI Blockade: Not Just Targeting Collagen Anymore? [PDF]
Arterioscler Thromb Vasc Biol, 2020 Gupta S, Brass LF.
europepmc +4 more sources
Glenzocimab does not impact glycoprotein VI-dependent inflammatory hemostasis [PDF]
Haematologica, 2020 Soumaya Jadoui +14 more
doaj +2 more sources
Is glycoprotein VI involved in contractual negotiations? [PDF]
Res Pract Thromb HaemostBrysland SA, Hearn JI, Gardiner EE.
europepmc +3 more sources
Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism [PDF]
Haematologica, 2020 Hanne Skille +9 more
doaj +2 more sources
Absence of bleeding upon dual antiplatelet therapy in a patient with a immune GPVI deficiency
Platelets, 2021 Acquired deficiencies in platelet glycoprotein VI are rare and have not been found associated with other defects. Here we report the case of a 64-year old male patient presenting an immune GPVI deficiency associated to a mutation in the alpha-actinin ...
Stéphane Loyau Inserm +5 more
doaj +1 more source
Platelets, 2021 Most agonists stimulate platelet Ca2+ rises via G-protein coupled receptors (GPCRs) or ITAM-linked receptors (ILRs). Well studied are the GPCRs stimulated by the soluble agonists thrombin (PAR1, PAR4), ADP (P2Y1, P2Y12), and thromboxane A2 (TP ...
Delia I. Fernández +2 more
doaj +1 more source
The future of glycoprotein VI as an antithrombotic target [PDF]
Journal of Thrombosis and Haemostasis, 2012 The treatment of acute coronary syndromes has been considerably improved in recent years with the introduction of highly efficient antiplatelet drugs. However, there are still significant limitations: the recurrence of adverse vascular events remains a problem, and the improvement in efficacy is counterbalanced by an increased risk of bleeding, which ...
Zahid, M +6 more
openaire +3 more sources
Efficient inhibition of collagen-induced platelet activation and adhesion by LAIR-2, a soluble Ig-like receptor family member. [PDF]
PLoS ONE, 2010 LAIR-1 (Leukocyte Associated Ig-like Receptor -1) is a collagen receptor that functions as an inhibitory receptor on immune cells. It has a soluble family member, LAIR-2, that also binds collagen and can interfere with LAIR-1/collagen interactions ...
Peter J Lenting +4 more
doaj +1 more source